Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Assets (2017 - 2025)

Aclaris Therapeutics has reported Assets over the past 9 years, most recently at $160.5 million for Q4 2025.

  • Quarterly results put Assets at $160.5 million for Q4 2025, down 27.17% from a year ago — trailing twelve months through Dec 2025 was $160.5 million (down 27.17% YoY), and the annual figure for FY2025 was $160.5 million, down 27.17%.
  • Assets for Q4 2025 was $160.5 million at Aclaris Therapeutics, down from $175.5 million in the prior quarter.
  • Over the last five years, Assets for ACRS hit a ceiling of $288.0 million in Q2 2021 and a floor of $160.5 million in Q4 2025.
  • Median Assets over the past 5 years was $219.3 million (2023), compared with a mean of $216.7 million.
  • Biggest five-year swings in Assets: skyrocketed 266.46% in 2021 and later plummeted 31.65% in 2024.
  • Aclaris Therapeutics' Assets stood at $251.2 million in 2021, then rose by 1.35% to $254.6 million in 2022, then decreased by 22.46% to $197.4 million in 2023, then rose by 11.61% to $220.3 million in 2024, then decreased by 27.17% to $160.5 million in 2025.
  • The last three reported values for Assets were $160.5 million (Q4 2025), $175.5 million (Q3 2025), and $189.1 million (Q2 2025) per Business Quant data.